Literature DB >> 22412226

Prolactin and its 16-kDa N-terminal fragment: are higher in patients with precapillary pulmonary hypertension than in a healthy control group.

Uta Hönicke1, Steffen Albrecht, Hagen Schrötter, Sabine Krug, Martin Kolditz, Eberhard Kuhlisch, Gert Höffken, Michael Halank.   

Abstract

We sought to determine whether patients with precapillary pulmonary hypertension show elevated serum levels of prolactin (PRL) and its 16-kDa N-terminal fragment (16-kDa PRL) and whether there is any correlation to measures of prognosis.Twenty-eight patients with idiopathic pulmonary artery hypertension, 15 with peripheral chronic thromboembolic pulmonary hypertension, and 4 with portopulmonary hypertension Child-Pugh class A were included. Our control subjects were 56 blood donors. Total prolactin was measured with an immunoluminometric assay. Antibodies against epitope C detected only the intact prolactin before it was split. The 16-kDa PRL was calculated from the difference between total and intact prolactin.Prolactin was significantly (P=0.009) higher in the study group (median, 190 mU/L; interquartile range, 162 mU/L) than in the control group (median, 140 mU/L; interquartile range, 91 mU/L). The 16-kDa PRL was significantly elevated in the study group (P=0.046). Prolactin and 16-kDa PRL correlated inversely with the 6-minute-walk distance (P <0.01) and with peak oxygen uptake during exercise (P <0.005).Serum levels of prolactin and 16-kDa PRL were significantly higher in patients with precapillary pulmonary hypertension and were inversely correlated with 6-minute-walk distance and peak oxygen uptake.These results indicate that prolactin and 16-kDa PRL might play a role in the pathophysiology of precapillary pulmonary hypertension.

Entities:  

Keywords:  Chronic thromboembolic pulmonary hypertension; hyperprolactinemia/blood; hypertension, portal; hypertension, pulmonary; idiopathic pulmonary arterial hypertension; prolactin 16-kDa fragment, human; prolactin/blood/chemistry

Mesh:

Substances:

Year:  2012        PMID: 22412226      PMCID: PMC3298933     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  23 in total

1.  Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms.

Authors:  Claudio Molinari; Elena Grossini; David A S G Mary; Francesca Uberti; Ezio Ghigo; Flavio Ribichini; Nicola Surico; Giovanni Vacca
Journal:  Endocrinology       Date:  2007-04-26       Impact factor: 4.736

2.  Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules.

Authors:  Z Dueñas; L Torner; A M Corbacho; A Ochoa; G Gutiérrez-Ospina; F López-Barrera; F A Barrios; P Berger; G Martínez de la Escalera; C Clapp
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-10       Impact factor: 4.799

3.  Prolactin-induced immunoglobulin and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals.

Authors:  M A Gutiérrez; J F Molina; L J Jara; C García; S Gutiérrez-Ureña; M L Cuéllar; A Gharavi; L R Espinoza
Journal:  Int Arch Allergy Immunol       Date:  1996-03       Impact factor: 2.749

4.  16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1/IFN regulatory factor-1 pathway.

Authors:  Sok-Hyong Lee; Michiya Nishino; Tuhina Mazumdar; Gabriela E Garcia; Matthew Galfione; Florence L Lee; Cynthia L Lee; Albert Liang; Jeri Kim; Lili Feng; N Tony Eissa; Sue-Hwa Lin; Li-Yuan Yu-Lee
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

Review 5.  Risk factors for chronic thromboembolic pulmonary hypertension.

Authors:  Irene Lang; Kim Kerr
Journal:  Proc Am Thorac Soc       Date:  2006-09

6.  Prolactin-induced expression of vascular endothelial growth factor via Egr-1.

Authors:  Anita S Goldhar; Barbara K Vonderhaar; Josephine F Trott; Russell C Hovey
Journal:  Mol Cell Endocrinol       Date:  2005-03-31       Impact factor: 4.102

7.  Specificity and clinical utility of methods for the detection of macroprolactin.

Authors:  Lucille Kavanagh; T Joseph McKenna; Michael N Fahie-Wilson; James Gibney; Thomas P Smith
Journal:  Clin Chem       Date:  2006-05-04       Impact factor: 8.327

8.  16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation.

Authors:  Carmen Gonzalez; Ana M Corbacho; Jason P Eiserich; Celina Garcia; Fernando Lopez-Barrera; Veronica Morales-Tlalpan; Alma Barajas-Espinosa; Mauricio Diaz-Muñoz; Rafael Rubio; Sue-Hwa Lin; Gonzalo Martinez de la Escalera; Carmen Clapp
Journal:  Endocrinology       Date:  2004-09-09       Impact factor: 4.736

9.  Prolactin stimulates ubiquitination, initial internalization, and degradation of its receptor via catalytic activation of Janus kinase 2.

Authors:  Gayathri Swaminathan; Bentley Varghese; Chellappagounder Thangavel; Christopher J Carbone; Alexander Plotnikov; K G Suresh Kumar; Elizabeth M Jablonski; Charles V Clevenger; Vincent Goffin; Luqin Deng; Stuart J Frank; Serge Y Fuchs
Journal:  J Endocrinol       Date:  2008-02       Impact factor: 4.286

10.  Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats.

Authors:  R Dumitrascu; C Kulcke; M Königshoff; F Kouri; X Yang; N Morrell; H A Ghofrani; N Weissmann; R Reiter; W Seeger; F Grimminger; O Eickelberg; R T Schermuly; S S Pullamsetti
Journal:  Eur Respir J       Date:  2010-10-14       Impact factor: 16.671

View more
  3 in total

1.  Prolactin stimulates sodium and chloride ion channels in A6 renal epithelial cells.

Authors:  Megan M Greenlee; Jeremiah D Mitzelfelt; Billie Jeanne Duke; Otor Al-Khalili; Hui-Fang Bao; Douglas C Eaton
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-13

Review 2.  From Bench to Bedside: Translating the Prolactin/Vasoinhibin Axis.

Authors:  Jakob Triebel; Maria Ludivina Robles-Osorio; Renata Garcia-Franco; Gonzalo Martínez de la Escalera; Carmen Clapp; Thomas Bertsch
Journal:  Front Endocrinol (Lausanne)       Date:  2017-12-11       Impact factor: 5.555

3.  Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute.

Authors:  Anna R Hemnes; David G Kiely; Barbara A Cockrill; Zeenat Safdar; Victoria J Wilson; Manal Al Hazmi; Ioana R Preston; Mandy R MacLean; Tim Lahm
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.